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Copy number alterations in 
B-cell development genes, drug 
resistance, and clinical outcome 
in pediatric B-cell precursor acute 
lymphoblastic leukemia
elisabeth M. p. steeghs1, Judith M. Boer1,2, Alex Q. Hoogkamer1, Aurélie Boeree1,  
Valerie de Haas3, Hester A. de Groot-Kruseman3, Martin A. Horstmann4, Gabriele escherich4, 
Rob pieters2,3 & Monique L. den Boer1,2,3
pediatric B-cell precursor acute lymphoblastic leukemia (BCp-ALL) is associated with a high frequency 
of copy number alterations (CNAs) in IKZF1, EBF1, PAX5, CDKN2A/B, RB1, BTG1, ETV6, and/or the 
PAR1 region (henceforth: B-cell development genes). We aimed to gain insight in the association 
between CNAs in these genes, clinical outcome parameters, and cellular drug resistance. 71% of newly 
diagnosed pediatric BCp-ALL cases harbored one or more CNAs in these B-cell development genes. 
the distribution and clinical relevance of these CNAs was highly subtype-dependent. In the DCoG-
ALL10 cohort, only loss of IKZF1 associated as single marker with unfavorable outcome parameters 
and cellular drug resistance. prednisolone resistance was observed in IKZF1-deleted primary high 
hyperdiploid cells (~1500-fold), while thiopurine resistance was detected in IKZF1-deleted primary 
BCR-ABL1-like and non-BCR-ABL1-like B-other cells (~2.7-fold). The previously described risk 
stratification classifiers, i.e. IKZF1plus and integrated cytogenetic and CNA classification, both predicted 
unfavorable outcome in the DCOG-ALL10 cohort, and associated with ex vivo drug cellular resistance 
to thiopurines, or L-asparaginase and thiopurines, respectively. this resistance could be attributed to 
overrepresentation of BCR-ABL1-like cases in these risk groups. taken together, our data indicate that 
the prognostic value of CNAs in B-cell development genes is linked to subtype-related drug responses.
Acute lymphoblastic leukemia (ALL) is the most common cancer diagnosed in children. The introduction of 
risk-adjusted treatment protocols has significantly improved survival rates, which nowadays is approaching 90% 
survival1–3. Outcome of B-cell precursor ALL (BCP-ALL) differs by genetic subtype, i.e. ETV6-RUNX1, high 
hyperdiploid, and TCF3-PBX1 cases have favorable prognosis, whereas BCR-ABL1, and KMT2A-rearranged 
BCP-ALL is associated with an unfavorable treatment outcome3. Approximately 25% of the patients has a 
genetically unclassified disease, which is defined as ‘B-other’. This heterogeneous group can be subdivided in 
BCR-ABL1-like patients and non-BCR-ABL1-like B-other patients4,5. Within the BCR-ABL1-like subtype intra-
chromosomal amplification of chromosome 21, dicentric chromosome (9;20), and kinase activating lesions 
are reported4–9. In non-BCR-ABL1-like B-other cases chromosomal translocations involving DUX4, ZNF384, 
and MEF2D were identified10–12. In addition to the major classifying abnormalities, secondary aberrations have 
been observed, including copy number alterations (CNAs) in genes involved in B-cell development (e.g. IKZF1, 
EBF1, PAX5, ETV6), cell cycle and proliferation (e.g. CDKN2A, CDKN2B, RB1, BTG1), and cytokine receptors 
(e.g. CRLF2)4,5,8,9,13–16. Interestingly, some of these genetic lesions (e.g. IKZF1) were shown to predict clinical 
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outcome5,14,17. The Dutch Childhood Oncology Group (DCOG) implemented IKZF1 status as risk factor in the 
ongoing DCOG-ALL11 protocol. In addition, risk stratification strategies were designed by integration of CNA 
profiles and genetic subtypes18–20.
Cellular drug resistance is an important cause of relapse. Ex vivo drug resistance at diagnosis is associated with 
high risk of early treatment failures21–23. In addition, BCP-ALL cells at relapse are more resistant towards gluco-
corticoids, L-asparaginase, anthracyclines, and thiopurines24. IKZF1 deletions are reported to mediate resist-
ance towards glucocorticoids, but the relationship between remaining CNAs and cellular drug resistance is yet 
unknown25–27. Therefore, we performed an explorative study, which aimed to gain insight in associations between 
CNAs, cellular drug resistance, and clinical outcome.
Results
A pediatric BCP-ALL cohort of 515 newly diagnosed cases, representing all major ALL subtypes, was screened 
for CNAs in eight genes involved in transcription of lymphoid genes and the differentiation and proliferation of 
precursor B-cells (henceforth: B-cell development genes; Supplementary Fig. 1). In total, 71% of the pediatric 
BCP-ALL cases harbored one or more CNAs in these B-cell development genes (Fig. 1). The CNA frequency 
differed between genetic BCP-ALL subtypes. The percentage of patients with one of more CNAs was the highest 
in BCR-ABL1-like cases and the lowest in TCF3-PBX1 cases (Supplementary Fig. 2A).
CNAs in B-cell transcription factors. IKZF1. Deletions of the transcription factor IKZF1 were detected 
in 20% of the BCP-ALL cases. This frequency differed between subtypes: IKZF1 deletions were enriched in 
BCR-ABL1 (65%) and BCR-ABL1-like (44%) cases, whereas deletions were low or absent in ETV6-RUNX1 (3%) 
and TCF3-PBX1 (0%), respectively (Fig. 1A; Supplementary Fig. 2B). In addition, 76% (78/102) of the cases with 
an IKZF1 deletion harbored CNAs in additional genes, which mainly involved PAX5 and CDKN2A/B (Fig. 2). 
This co-occurrence was subtype dependent: a strong association (OR >2, p < 0.001) was observed in BCR-ABL1, 
BCR-ABL1-like and B-other cases, whereas in high hyperdiploid cases IKZF1 deletions mainly occurred inde-
pendent of CNAs in PAX5 and/or CDKN2A/B. Within the group of genetically unclassified patients, loss of IKZF1 
associated with dicentric chromosome (9;20) and tyrosine kinase fusion genes (Supplementary Table 1).
IKZF1-deleted cases more often showed high MRD levels (≥10−3) after induction therapy (TP1; p = 0.013), 
and intermediate MRD levels (10−4 ≤ MRD < 10−3) after the first consolidation course (TP2; p = 0.028), com-
pared to IKZF1-wildtype cases (Fig. 3A). This association could be predominantly attributed to high MRD 
levels in BCR-ABL1-like and B-other cases, but was not observed in high hyperdiploid or ETV6-RUNX1 cases 
(Supplementary Figs 3–6). In addition, IKZF1-deleted cases more often suffered from a non-response or relapse 
compared to IKZF1-wildtype cases (5-year CIR: 30.4% versus 9.0%; p < 0.001; Fig. 4A,B), confirming previous 
findings5,14,17. An IKZF1 deletion remained predictive for an unfavorable outcome in DCOG-ALL10 cases treated 
in the medium risk arm (Fig. 4B), indicating that the prognostic value of IKZF1 is independent of the early treat-
ment response monitored by MRD.
As cellular drug resistance might underlie this poor outcome, we examined the ex vivo efficacy of chem-
otherapeutic agents that are commonly used during induction and consolidation therapy. Primary BCP-ALL 
cells harboring IKZF1 deletions were more resistant to prednisolone and thiopurines compared to IKZF1 wild-
type cells (p < 0.05; Fig. 5A,B). Resistance against these agents was subtype dependent, as visualized in Fig. 5B: 
prednisolone resistance was predominantly observed in high hyperdiploid cells (~1500-fold, p = 0.009), whereas 
thiopurine resistance (6-thioguanine (1.6 fold, p = 0.011) and 6-mercaptopurine (1.7 fold, p < 0.001)) was mainly 
identified in IKZF1-deleted BCR-ABL1-like and B-other cells (Fig. 5B). Moreover, high hyperdiploid cells with a 
deletion of IKZF1 were more resistant to L-asparaginase(Supplementary Fig. 8A).
EBF1. The transcription factor EBF1 was deleted in a minority (6%) of the BCP-ALL cases (Fig. 1B). Deletions 
were enriched in BCR-ABL1-like cases (15%), but absent in KMT2A-rearranged and TCF3-PBX1 cases (Fig. 1B). 
Cases that harbored an EBF1 deletion showed a trend towards higher MRD levels after induction therapy com-
pared to non-EBF1 deleted cases (OR = 5.16, p = 0.057; Fig. 3B). No association between loss of EBF1 and cellular 
drug resistance was observed, though drug resistance data were only available for six EBF1 deleted cases.
PAX5. CNAs of the transcription factor PAX5 were observed in 28% of the BCP-ALL cases (Fig. 1C). CNAs 
were detected throughout all BCP-ALL subtypes, although the frequency was relatively high in BCR-ABL1 (50%) 
and BCR-ABL1-like (46%) cases (Fig. 1C). The strong co-occurrence of PAX5 and CDKN2A/B CNAs (Fig. 2, 
OR = 6.36, p < 0.001) is likely caused by the high frequency of chromosome 9p deletions observed in these 
cases28; the chromosome arm on which PAX5 and CDKN2A/B are located. In correspondence, chromosome 
9p deletions were observed in 51.8% (44/85) of these cases. Despite of the strong association between PAX5 
CNAs and IKZF1 deletions (Fig. 2, OR = 2.94, p < 0.001), CNAs in PAX5 were not predictive for high MRD levels 
(Fig. 3C) nor a poor prognosis in pediatric BCP-ALL cases (Fig. 4A). Strikingly, leukemic cells harboring CNAs 
in PAX5 showed an increased sensitivity (~5.1 fold, p = 0.008) to prednisolone compared to PAX5-wildtype cells 
(Fig. 5C). This difference in sensitivity was only significant (p = 0.031) in ETV6-RUNX1 cases, but a similar pat-
tern was also observed in the remaining BCP-ALL subtypes (Fig. 5C). Interestingly, this association depended on 
the IKZF1 status: cells with both an IKZF1 deletion and a CNA in PAX5 were equally sensitive to prednisolone as 
IKZF1 and PAX5 wildtype cells, whereas cells with only an IKZF1 deletion were more resistant to prednisolone 
(Supplementary Fig. 8B). These results suggest that CNAs in PAX5 might compensate for prednisolone resistance 
induced by loss of IKZF1.
ETV6. Deletions of the transcription factor ETV6 were detected in all BCP-ALL subtypes, but were especially 
enriched in ETV6-RUNX1 cases (71%; Fig. 1D). After induction therapy (TP1), ETV6-deleted cases more often 
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showed low (<10−4) MRD levels compared to ETV6-wildtype cases (Fig. 3D; OR = 2.6, p = 0.02). However, 
this association was subtype dependent: in BCR-ABL1-like and B-other cases an adverse association between 
ETV6 deletions and MRD levels was observed (Supplementary Fig. 3). Prognosis of cases with loss of ETV6 
was not different compared to ETV6-wildtype cases (Fig. 4). ETV6-deleted cells appeared to be more sensitive 
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Figure 1. CNA landscape of B-cell development genes in the different subtypes of pediatric BCP-ALL. CNA 
profile of 515 newly diagnosed pediatric BCP-ALL patients, representing all major BCP-ALL subtypes, was 
determined using MLPA. Association between CNAs and subtypes was studied using the Fisher Exact test. The 
proportion of patients per subtype with a specific CNAs is shown. CNAs tested included IKZF1 (A), EBF1 (B), 
PAX5 (C), ETV6 (D), CDKN2A/B (E), RB1 (F), BTG1 (G), PAR1 (H). **p ≤ 0.01, *p ≤ 0.05. del = deletion.
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to prednisolone (~3.2 fold, p = 0.046), but more resistant to vincristine (~1.8 fold, p < 0.01) and daunorubicin 
(~1.9 fold, p = 0.028). Remarkably, loss of the wildtype ETV6 allele in ETV6-RUNX1-positve cells associated 
with a high sensitivity to vincristine instead of resistance (p = 0.013, Fig. 5D), suggesting that associations of 
vincristine resistance differ between genetic subtypes of ALL. Moreover, deletion of ETV6 was associated with 
L-asparaginase resistance in high hyperdiploid cells and high 6-thioguanine sensitivity in ETV6-RUNX1 cells 
(Supplementary Fig. 8C).
CNAs in cell cycle and proliferation genes. CDKN2A/B. Deletions of the cell cycle regulators CDKN2A 
and/or CDKN2B were often observed (33%) in the pediatric BCP-ALL cohort (Fig. 1E). Similar to PAX5, the 
deletions in CDKN2A/B were found in all BCP-ALL subtypes, but were especially enriched in BCR-ABL1 (65%, 
OR = 3.95, p = 0.003), BCR-ABL1-like (54%, OR = 2.88, p < 0.001), and B-other cases (OR = 1.67, p = 0.026). No 
association with clinical outcome parameters or cellular drug resistance was observed (Figs 3–5).
RB1. The cell cycle regulator RB1 was deleted in a minority (~7%) of the BCP-ALL cases (Fig. 1F) and dele-
tions were detected in all BCP-ALL subtypes. Within the DCOG-ALL10 cohort, RB1-deleted cases showed a 
trend towards a poor event free survival (5- year EFS: 68.2% versus 86.7%, p = 0.057), which was caused by an 
unfavorable response in the medium risk (MR) treatment group (5-year EFS: 46.9% versus 88.3%, p = 0.003; 
Supplementary Fig. 7A). No association with MRD levels or cellular resistance to the tested drug panel was 
observed (Fig. 5).
BTG1. The anti-proliferative gene BTG1 was deleted in a minority (~8%) of the BCP-ALL cases. No deletions 
were detected in KMT2A-rearranged or TCF3-PBX1 cases, whereas the highest frequency was observed in 
BCR-ABL1 (30%) and ETV6-RUNX1 (16%) cases (Fig. 1G). Four out of five BTG1-deleted BCR-ABL1-like and 
B-other cases also harbored an IKZF1 deletion. These four cases all experienced an event and only the patient 
with wildtype IKZF1 remained in remission (Supplementary Fig. 7B). This finding underlines an earlier report, 
in which a cooperative effect of BTG1 and IKZF1 lesions in leukemogenesis was observed27.
CNAs in cytokine receptors. PAR1. Deletions in the pseudoautosomal region 1 (PAR1) were the least 
prevalent (~4%) in this pediatric BCP-ALL cohort. CNAs in this region indicate presence of interstitial deletions 
or a translocation, which both induce overexpression of CRLF229. Deletions of the PAR1 region were detected in 
BCR-ABL1-like (11%), B-other (10%), and high hyperdiploid cases (2%), but not in remaining BCP-ALL sub-
types (Fig. 1H). Unfortunately, power was lacking to reliable study the association between deletions in the PAR1 
region, MRD levels, clinical prognosis, and cellular drug resistance.
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Figure 2. Co-occurence of CNAs in B-cell development genes in the different BCP-ALL subtypes. Heatmap of 
CNA profile of 515 newly diagnosed pediatric BCP-ALL patients, representing the major BCP-ALL subtypes. 
CNAs are shown per subtype. Colors indicate presence of a CNA and absence of CNAs is shown in white. The 
heatmap is sorted on IKZF1 deletions followed by CNAs in PAX5. Each column represents an individual patient. 
The co-occurrence between the different CNAs in all BCP-ALL cases was calculated using the Fisher Exact test. 
Odds ratios and p-values of significant associations are shown.
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Taken together, with the exception of loss of the IKZF1 gene, none of the CNAs in the remaining B-cell devel-
opment genes strongly associates with clinical outcome and cellular drug resistance as single marker. Our results 
show that the clinical value of CNAs in B-cell development genes is highly context dependent and differs between 
the diverse oncogenic drivers of pediatric BCP-ALL.
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Figure 3. The association between CNAs and MRD levels after induction therapy and the first consolidation 
course in newly diagnosed BCP-ALL. MRD levels of DCOG-ALL treated BCP-ALL cases (all risk groups) 
after induction (TP1; n = 183) and first consolidation course (TP2; n = 183). The percentage of cases with high 
(≥10−3), medium (10−4 ≤ MRD < 10−3), and undetectable MRD levels (<10−4) is depicted per CNA. The Fisher’s 
Exact test was applied to study associations between CNAs and MRD levels. **p ≤ 0.01, *p ≤ 0.05. del = deletion.
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Risk stratification classifiers. In recent studies, IKZF1plus and integrated cytogenetic and CNA classifi-
cation were shown to be prognostic classifiers18,20. In the DCOG-ALL10 cohort 12 of the 210 cases were clas-
sified as IKZF1plus20. The prognosis of IKZF1plus cases was unfavorable compared to cases with wildtype IKZF1 
(Supplementary Fig. 9). Strikingly, no prednisolone resistance was observed in IKZF1plus cells, which could be 
explained by underrepresentation of high hyperdiploid cases in this group (n = 1, Fig. 5A). However, IKZF1plus 
cases did show ex vivo resistance to 6-thioguanine and 6-mercaptopurine, mainly caused by the high proportion 
of BCR-ABL1-like and B-other cases in this group.
Integration of cytogenetic and CNA data as reported by Moorman et al.18 identified cases with a genetic good 
and poor risk. Cases that were classified as poor risk showed an unfavorable 5-years EFS and CIR compared good 
risk cases, as shown in Supplementary Fig. 10A. These genetically poor risk cases showed high MRD levels after 
induction therapy and the first block of consolidation therapy, indicating a poor response to drugs that are used 
during these treatment phases (Supplementary Fig. 10B). Indeed, ex vivo cellular drug response data showed 
resistance of poor risk cells to L-asparaginase, 6-thioguanine, and 6-mercaptopurine (Fig. 5A, Supplementary 
Fig. 10C). Enrichment of BCR-ABL1-like cases could attribute to the thiopurine and L-asparaginase resistance 
observed in the poor risk group4.
Discussion
BCP-ALL cases harbor various genetic aberrations in genes involved in lymphoid maturation, cell cycle reg-
ulators, tumor suppressors, and tyrosine kinases. We performed an explorative study to gain insight in the 
association between CNAs in B-cell development genes, MRD levels, long-term prognosis, and cellular drug 
resistance. Interestingly, the distribution and clinical relevance of these CNAs was subtype-dependent. A high 
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Figure 4. Prognostic value of CNAs in DCOG-ALL10 treated cases. (A) The association between CNAs in all 
risk groups and cumulative incidence of relapse (CIR) and event-free-survival (EFS) was examined. BCP-ALL 
patients (n = 210) were treated according to DCOG-ALL10 protocol. CIR was estimated using a competing risk 
model. Relapse and non-response were considered as event, and death as competing event. To test equality of 
the CIRs, the Gray’s test was applied. Non-response, relapse, and death were considered as events for EFS. EFS 
rates were determined using Cox regression, and compared using the Wald test. For reliable test results, groups 
should contain at least 5 cases. (B) CIR and EFS curves of cases without or with an IKZF1 deletion. Curves 
contain either all risk groups, or the medium risk arm only.
7Scientific RepoRts |          (2019) 9:4634  | https://doi.org/10.1038/s41598-019-41078-4
www.nature.com/scientificreportswww.nature.com/scientificreports/
0.0 FC > 1, p < 0.05
FC < 1, p < 0.05
ND
A
B
C
D
p > 0.05
PR
ED
VC
R
AS
P
DN
R
6-M
P
6-T
G
PR
ED
VC
R
AS
P
DN
R
6-M
P
6-T
G
PR
ED
VC
R
AS
P
DN
R
6-M
P
6-T
G
PR
ED
VC
R
AS
P
DN
R
6-M
P
IKZF1 3.9 0,13 0,31 0,29 1.6 1.7 0,66 0,18 0,46 0,12 0,10 2.9 1515 0,12 23 0,43 0,00 0,00 0,00 0,00 0,00 0,00
EBF1 0,65 0,75 0,20 0,12 0,60 0,12 0,41 0,45 0,26 0,66 0,77 0,21 0,0 0,0 0,0 0,0 0,0 0,0 0,90 0,87 0,56 0,23 0,24 0,60
PAX5 0.2 0,69 1,00 0,79 0,15 0,52 0,12 0,84 0,86 0,50 0,22 0,68 0,3 0,8 0,6 0,8 0,2 0,7 0.3 0,96 0,34 0,15 0,91 0,12
ETV6 0.3 1.8
1.8 1.7
1.219 1.6
0,10 1.9 0,80 0,79 0,75 0,07 0,20 0,07 0,92 0,38 0,5 0,3 0,1 0,9 0,05 0.5 0,77 0,19 0.7 0,20
CDKN2A/B 0,84 0,20 0,19 0,32 0,15 0,88 0,78 0,22 0,80 0,54 1.9 0,94 0,3 0,1 0,8 0,6 0,78 0,73 0,65 0,19 0,66 0,51
RB1 0,14 0,21 0,90 0,43 0,95 0,65 0,13 0,35 0,73 0,91 0,74 0,70 0,0 0,1 0,0 0,0 0,7 0,2 0,13 0,66 0,72 0,13 0,12 0,22
BTG1 0,10 0,42 0,70 0,87 0,37 0,18 0,38 0,36 0,10 0,56 0,85 3.6 0,4 0,8 0,3 0,2 0,6 0,7 0,37 0,42 0,28 0,95 0,80 0,64
P
Poor risk
CNAs
Risk classifiers
AR1
IKZF1plus
0,29 0,78 0,71 0,58 0,51 0,98 0,29 0,96 0,44 0,78 0,50 0,82 0,4 0,4 0,2 0,7 0,9 0,5 0,00 0,00 0,00 0,00 0,00 0,00
, 00,05,0
Total BCP-ALL
n = 161 
BCR-ABL1-like/ B-other
n = 56 
High hyperdiploid
n = 43 
ETV6-RUNX1
n = 49
6-T
G
IK
ZF
1
ET
V6
6-Mercaptopurine
< 0.016
0.1
> 0.5
LC
50
All
Subtypes
BCR-ABL1-like/
B-other
** *
6-Thioguanine
< 0.002
0.01
> 0.05
LC
50
All
Subtypes
BCR-ABL1-like/
B-other
**
Prednisolone
0.1
1
10
100
> 250
< 0.008
LC
50
All
Subtypes
BCR-ABL1-like/
B-other
High 
Hyperdiploid
***
No
 de
l (n
=9
8)
IK
ZF
1 de
l (n
=2
2)
No
 de
l (n
=2
1)
IKZ
F1
 de
l (n=
18
)
No
 de
l (n
=9
6)
IK
ZF1
 de
l (n
=2
0)
No
 de
l (n
=2
1)
IKZ
F1
 de
l (n
=1
6)
No
 de
l (n
=1
28
)
IKZ
F1 
del
 (n
=3
1)
No
 de
l (n
=3
5)
IKZ
F1 
de
l (n
=2
1)
No
 D
el 
(n=
35
)
IK
ZF1
de
l (n
=8
)
Prednisolone
No
 de
l (n
=1
07
)
ET
V6
 de
l (n
=5
2)
No
 del
 (n
=4
4)
ET
V6
 de
l (n
=1
2)
No
 de
l (n
=3
8)
ET
V6
 de
l (n
=5
)
No
 de
l (n
=1
4)
ET
V6
 de
l (n
=3
5)
0.1
1
10
100
> 250
< 0.008
LC
50
ETV6-
RUNX1
All
Subtypes
BCR-ABL1-like/
B-other
High 
Hyperdiploid
**
Vincristine
No
 de
l (n
=1
06
)
ET
V6
de
l (n
=5
1)
No
 de
l (n
=4
2)
ET
V6
 de
l (n
=1
2)
No
del
 (n
=3
9)
ET
V6
 de
l (n
=5
)
No
de
l (n
=3
4)
ET
V6
de
l (n
=1
4)
0.1
1
10
> 50
< 0.048
LC
50
ETV6-
RUNX1
All
Subtypes
BCR-ABL1-like/
B-other
High 
Hyperdiploid
** *
PA
X5
Prednisolone
No
 C
NA
 (n
=1
20
)
PA
X5
CN
A 
(n=
39
)
No
 C
NA
 (n
=3
5)
PA
X5 
CN
A 
(n=
21
)
No
 C
NA
 (n
=4
2)
PA
X5 
CN
A 
(n=
1)
No
CN
A 
(n=
34
)
PA
X5 
CN
A 
(n=
15
)
0.1
1
10
100
> 250
< 0.008
LC
50
ETV6-
RUNX1
All
Subtypes
BCR-ABL1-like/
B-other
High 
Hyperdiploid
****
Figure 5. The association between CNAs and the ex vivo cellular drug response. (A) Leukemic cells were 
incubated for four days with a concentration range of prednisolone (µg/ml), vincristine (µg/ml), L-asparaginase 
(IU/ml), daunorubicin (µg/ml), 6-mercaptopurine (µg/ml), and 6-thioguanine (µg/ml), after which cell viability 
was measured using an MTT assay. The Mann-Whitney U test was applied to compare LC50-values. No 
association is depicted in grey, resistance in blue (p < 0.05, fold induction (FI) > 1), sensitive in green (p < 0.05, 
FI < 1), and not determined in white. The number of cases that were tested for prednisolone is depicted, 
and represent the maximum number of cases. For reliable test results, groups should contain at least 5 cases 
(groups ≤ 5 are depiced as ND). Results of single CNAs are depicted for all risk groups and for BCR-ABL1-
like/B-other cells, high hyperdiploid cells, and ETV6-RUNX1 cells. In addition, associations between the risk 
classifiers IKZF1plus and integrated cytogenetic and CNA classification (poor risk) and cellular drug resistance 
are shown18,20. (B) LC50 values for prednisolone (µg/ml), 6-thiogunanine (µg/ml), and 6-mercaptopurine 
(µg/ml) of cases without or with IKZF1 deletion. Columns include all BCP-ALL subtypes (grey), BCR-ABL1-
like/B-other cells (blue), and high hyperdiploid cells (green). The red line represent the median LC50 value 
in the each group. (C) LC50 values for prednisolone (µg/ml) of cases without or with PAX5 CNAs. Columns 
include all BCP-ALL subtypes (grey), BCR-ABL1-like/B-other cells (blue), high hyperdiploid cells (green), and 
ETV6-RUNX1 cells (yellow). The red line represent the median LC50 value in the each group. (D) LC50 values 
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frequency of CNAs in these B-cell development genes was found in the poor prognostic subtypes BCR-ABL1, 
BCR-ABL1-like, and B-other. Cooperative lesions may favor the aggressive phenotype of a leukemia, such as 
exemplified by the synergistic effect between loss of IKZF1 and the BCR-ABL1 fusion gene in leukemogene-
sis30, and the antagonizing effect of IKZF1 deletions in the response to imatinib31. In contrast, the prognosis of 
ETV6-RUNX1, DUX4-rearranged, and ERG-deleted BCP-ALL is probably not affected by IKZF1 deletions, but 
numbers with IKZF1 deletions in these subtypes are low11,12,15,32,33. These observations indicate that the genetic 
context influences the functional effect of CNAs in B-cell development genes. The importance of the genetic 
context is exemplified by the fact that isolated deletions of BTG1 do not affect cellular drug resistance or the 
prognosis of BCP-ALL cases, whereas all four patients with concomitant loss of BTG1 and IKZF1 experienced an 
event. Moreover, combined loss BTG1 and IKZF1 was shown to enhance glucocorticoid resistance27. In contrast 
to BTG1-IKZF1 synergy, we observed that CNAs in PAX5 may counteract the effect of an IKZF1 deletion on 
prednisolone resistance. Various combinations of cooperative lesions may therefore have different effects on the 
pathobiology of B-cell precursor ALL cells.
In the present study we observed an association between deletion of IKZF1 and prednisolone resistance, espe-
cially in high hyperdiploid cells. In correspondence, a direct association has been demonstrated between IKZF1 
deletion and glucocorticoid-induced cell death25,34. IKZF1 functions as a metabolic gatekeeper and consequently 
loss of IKZF1 results in increased intracellular ATP and glucose levels34. Interestingly, we previously observed a 
direct relation between an increased glycolytic rate and prednisolone resistance in primary BCP-ALL cells35,36. In 
these leukemic cells, inhibition of glycolysis restored the efficacy of prednisolone36. Hence, inhibition of glycolysis 
might also be a potential treatment strategy to re-sensitize IKZF1-deleted cells to prednisolone and should be 
explored in more detail in future studies, also in the context of BTG1 and PAX5.
In contrast to high hyperdiploid cells, deletion of IKZF1 was not linked to prednisolone resistance in primary 
BCR-ABL1-like and B-other ALL cells, suggesting that additional factors (e.g. differentiation stage, other onco-
genic drivers) are important for the functional effect of a deletion of the IKZF1 gene in these type of cells. Instead 
of prednisolone resistance, we observed thiopurines resistance in these BCR-ABL1-like and B-other ALL cells. 
Thiopurine resistance might be caused by deficiencies in the DNA mismatch repair system and indeed DNA 
repair genes were reported to be downregulated in IKZF1-deleted cells37,38. Interestingly, this characteristic might 
offer opportunities to target these leukemic cells via the DNA mismatch repair apparatus, e.g. by PARP inhibitors, 
and warrants further studies.
Besides IKZF1, deletion of RB1 was predictive for a poor outcome in the MR-risk group of the DCOG-ALL10 
cohort. RB1 deletions are known to be enriched in poor prognostic iAMP21 and hypodiploid cases, which might 
explain the unfavorable outcome of RB1-deleted cases13,39,40. However, the unfavorable outcome could not be 
explained by or cellular resistance against induction therapy drugs.
Recently, two independent studies showed that integration of genetic aberrations improved the risk stratifica-
tion of BCP-ALL in children18,20. Both IKZF1plus and integrated cytogenetic and CNA classification predicted poor 
outcome in the DCOG-ALL10 cohort, and associated with drug resistance to thiopurines, or L-asparaginase and 
thiopurines, respectively. The cellular drug resistance could be attributed to overrepresentation of BCR-ABL1-like 
cases in these risk groups4. Taken together, our results suggest that the prognostic value of CNAs in B-cell devel-
opment genes is linked to subtype-related drug resistance.
In the current study, we restricted our analyses to CNAs in eight genes that are recurrently deleted in pediatric 
BCP-ALL. However, additional genetic aberrations may be of importance for prognosis and cellular drug resist-
ance and should be explored in future research. Moreover, as we performed an explorative study, it is of impor-
tance to confirm the associations that are proposed in the present paper in independent studies.
In conclusion, results obtained in the present study revealed that, with the exception of an IKZF1 deletion, 
none of the remaining CNAs as single marker associated both with an unfavorable clinical prognosis and cellular 
drug resistance. Our results indicate that the biological and clinical importance of CNAs in B-cell development 
genes (and presumably also other genetic aberrations) is highly context dependent and differs between the diverse 
oncogenic drivers of pediatric BCP-ALL. Functional studies that focus on potential causes of cellular drug resist-
ance should therefore take the oncogenic driver and additional genetic aberrations into account.
Methods
processing of primary patient material. Bone marrow and/or peripheral blood samples were obtained 
from children (1–18 years) with newly diagnosed ALL. Written informed consent was obtained from parents 
or guardians to use excess of diagnostic material for research purposes, as approved by the Medical Ethics 
Committee of the Erasmus Medical Center, The Netherlands. These studies were conducted in accordance with 
the Declaration of Helsinki. Mononuclear cells were isolated using Lymphoprep gradient separation and the 
leukemic blast percentage was determined microscopically by May-Grünwald Giemsa stained cytospin prepa-
rations, as described previously21. Samples were enriched to over 90% purity of leukemic cells by depletion of 
non-leukemic cells using immunomagnetic beads. Primary leukemic cells were maintained in RPMI-1640 Dutch 
modification supplemented with 20% fetal calf serum (Integro), with 0.1% insulin-transferrin-sodium selenite 
(Sigma), 0.4 mM glutamine (Invitrogen), 0.25 μg/ml gentamycine (Gibco), 100 IU/ml penicillin (Gibco), 100 μg/
ml streptomycin (Gibco), 0.125 μg/ml fungizone (Gibco).
for prednisolone (µg/ml), vincristine (µg/ml), and daunorubicin (µg/ml) of primary leukemic cells without or 
with ETV6 deletion. Columns include all BCP-ALL subtypes (grey), BCR-ABL1-like/B-other cells (blue), high 
hyperdiploid cells (green), and ETV6-RUNX1 cells (yellow). The red line represent the median LC50 value in the 
each group. *p < 0.05, **p < 0.01; Mann-Whitney U test.
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The major cytogenetic subtypes, i.e. high hyperdiploid (>50 chromosomes), ETV6-RUNX1, TCF3-PBX1, 
KMT2A-rearranged, BCR-ABL1, BCR-ABL1-like, and B-other (negative for all before mentioned genomic 
lesions), were determined using fluorescent in situ hybridization and (RT-)PCR. The 110-probeset gene expres-
sion classifier was used to identify BCR-ABL1-like cases4. Patients were treated according to the Dutch Childhood 
Oncology Group (DCOG)-ALL8, -ALL9, -ALL10, the EsPhALL protocol, or the COALL-06-97 and COALL-07-
03 study protocols3,14,41,42. Patient characteristics were provided by the central study centers of DCOG, The Hague, 
the Netherlands and COALL, Hamburg, Germany. PCR-detected MRD was evaluated according to the EuroMRD 
guidelines3,43,44.
Multiplex Ligation-Dependent Probe Amplification. To identify genomic lesions in IKZF1, CDKN2A, 
CDKN2B, ETV6, PAX5, RB1, BTG1, EBF1, and the PAR1 region (CSF2RA/IL3RA/CRLF2), the SALSA P335 
ALL-IKZF1 (a3) and the SALSA P202 Multiplex Ligation-dependent Probe Amplification (MLPA) assays 
(MRC-Holland, Amsterdam, Netherlands) were used as described previously14. In short, DNA fragments with 
incorporated FAM nucleotides were generated using 125 ng of genomic DNA, according to the manufacturer’s 
protocol. To quantify the amplified fragments, an ABI-3130 genetic analyzer (Applied Biosystems, Carlsbad, CA) 
was used. The manufacturer’s control probes were used to normalize peak intensities, as well as a synthetic control 
reference generated from five normal DNA samples in the same MLPA run (normal copy number = 0.75 ≤ peak 
ratio ≤ 2.0; deletions = peak ratio < 0.75; gain = peak ratio > 2.0). A deletion was defined by a peak ratio below 
0.75 for at least one MLPA-probe per gene. CDKN2A/B deletions included loss of either CDKN2A or CDKN2B. 
The effect of intragenic amplifications and/or deletions in PAX5 were analyzed within one group, as they were 
predicted to be functionally equivalent18,45. Loss of the PAR1 region was defined by deletion of both IL3RA 
and CSF2RA probes while expression of the CRLF2 and SHOX-AREA probes was maintained. MLPA analyses 
were performed in 515 BCP-ALL cases, representing the major genetic subtypes in childhood ALL, i.e. 3.9% 
BCR-ABL1, 17.3% BCR-ABL1-like, 20.2% non-BCR-ABL1-like B-other, 28.7% ETV6-RUNX1, 24.5% high hyper-
diploid, 1.6% KMT2A-rearranged, 3.9% TCF3-PBX1.
Clinical characteristics and statistics. To identify whether CNAs were underrepresented or enriched 
in a subtype, the Fisher’s exact test was applied using R software (version 3.2.1). Obtained odds ratios (ORs), 
95% confidence interval, and p-values are reported. The Fisher’s exact test was also applied to compare mini-
mal residual disease (MRD) levels after induction and first consolidation therapy between patients groups with 
CNAs and wildtype patients. Cumulative incidence of relapse (CIR) was estimated using a competing risk model 
and significance was determined using the Gray’s test. Relapse and non-response (counted as event at day 79) 
were considered as event, with death as competing event. Event-free survival (EFS) probabilities were estimated 
using cox regression and compared using the Wald test. Relapse, non-response, secondary malignancies and 
death were counted as events. Outcome analyses were performed in R (version 3.2.1), using the packages cmprsk 
version 2.2–746, mstate version 0.2.747 and survival version 2.38–448. Five-year EFS and CIR are reported. The 
DCOG-ALL10 trial is the most recently completed nationwide trial in which patients were risk-stratified by mini-
mal residual disease (MRD) levels and for whom sufficient long-term follow-up data were available. Therefore, we 
restricted the analysis of associations between CNAs and clinical response parameters (MRD, clinical outcome) 
to this cohort. In addition, the genetic subtypes are represented with a distribution that is comparable to the gen-
eral pediatric BCP-ALL population (excluding BCR-ABL1-positive cases since these patients are eligible for the 
EsPhALL protocol), i.e.12.2% BCR-ABL1-like, 13.9% non-BCR-ABL1-like B-other, 33.5% ETV6-RUNX1, 32.7% 
high hyperdiploid, 2.0% KMT2A-rearranged, and 5.7% TCF3-PBX1 positive cases. The clinical characteristics of 
this cohort are displayed in Supplementary Table 2.
Ex vivo drug resistance assays. Ex vivo cytotoxicity of prednisolone, vincristine, L-asparaginase, 
daunorubicin, 6-mercaptopurine, and 6-thioguanine was evaluated using 3-(4,5-dimethylthiazolyl-2)-2,5-di-
phenyltetrazolium bromide (MTT), as previously described21. In brief, cells were exposed to a concentration 
range of chemotherapeutics (prednisolone: 0.008 to 250 μg/mL; vincristine: 0.05 to 50 μg/mL; L-asparaginase: 
0.003 to 10 IU/mL; daunorubicin: 0.002 to 2 μg/ml; 6-mercaptopurine: 15.6 to 500 μg/ml; and 6-thioguanine: 
1.56 to 500 μg/ml) in a 96 wells plates for four days at 37 °C and 5% CO2. After four days of culture, samples were 
included if control wells harbored more than 70% leukemic cells and an optical density higher than 0.050 arbi-
trary units (adjusted for blank values). The concentration of drug lethal to 50% of the cells (LC50) was calculated. 
LC50-values were compared by the Mann-Whitney U test and adjusted for tied ranks if applicable.
Data Availability
The datasets generated during and/or analyzed during the current study are available from the corresponding 
author on reasonable request.
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